^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Squamous Cell Carcinoma of Head and Neck |
| Regimen: | TPeX (cisplatin + docetaxel + Erbitux (cetuximab)) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Excerpt:
Platinum/5-FU/cetuximab remains the standard therapy for recurrent/metastatic patients with SCCHN not expressing PD-L1 [I, A; ESMO-MCBS v1.1 score: 3]. TPeX is also a treatment option in this population [II, B].
